Targeting Adaptive IRE1α Signaling and PLK2 in Multiple Myeloma: Possible Anti-Tumor Mechanisms of KIRA8 and Nilotinib.
Yusuke YamashitaShuhei MoritaHiroki HosoiHiroshi KobataShohei KishimotoTatsuya IshibashiHiroyuki MishimaAkira KinoshitaBradley J BackesKoh-Ichiro YoshiuraFeroz R PapaTakashi SonokiShinobu TamuraPublished in: International journal of molecular sciences (2020)
Dominant activation of adaptive IRE1α was established in patients with MM. Both KIRA8 and nilotinib exhibited anti-myeloma effects, which were enhanced by bortezomib. Adaptive IRE1α signaling and PLK2 could be potential therapeutic targets and biomarkers in MM.